Nakatoh Shinichi
Department of Orthopedic Surgery, Asahi General Hospital, Japan.
Clin Calcium. 2009 Dec;19(12):1756-67.
FRAX is developed based on the use of clinical risk factor with or without bone mineral density. It would be expected in diagnosis of osteoporosis that FRAX(R) would be used in a group examination, in medical institution which does not have DEXA, and at home. However, results of FRAX are expressed as percentage indication which is not familiar to Japanese. We did questionnaire survey to the osteoporosis patient about the results of FRAX. As a result, fracture risk is thought of seriously by the initial diagnosis patient, the younger patient, and the patient with interest in osteoporosis. It is necessary to explain fracture risk of FRAX on the basis of patient background in clinical use.
FRAX是基于使用临床风险因素（有或无骨密度）而开发的。预计在骨质疏松症的诊断中，FRAX®将用于团体检查、没有双能X线吸收法（DEXA）的医疗机构以及家庭中。然而，FRAX的结果以百分比表示，这对日本人来说并不熟悉。我们对骨质疏松症患者进行了关于FRAX结果的问卷调查。结果显示，初诊患者、年轻患者以及对骨质疏松症感兴趣的患者会认真考虑骨折风险。在临床应用中，有必要根据患者背景来解释FRAX的骨折风险。
